Home – CDMO Solutions | GMP manufacturing
GMP manufacturing services for cell and gene therapy
OXB delivers reliable GMP manufacturing of viral vectors to support your program from first-in-human trials through global commercial launch. Leveraging state-of-the-art facilities, robust processes, and innovative technologies, we provide scalable, high-yield, and regulatory-ready manufacturing for multiple vector types.
Benefit from our rigorous controls: our quality-focused GMP processes and robust analytics ensure comprehensive, end-to-end CMC support, guiding your viral vector product through every stage of development and into commercialization with confidence.
Why choose OXB for GMP manufacturing?
Our world-class GMP manufacturing services provide unmatched advantages:
Proven track record
Licensed therapies successfully delivered from our GMP sites worldwide.
Flexible capacity
Bioreactor systems and fill-finish suites to support both clinical and commercial programs.
Experienced team
Scientists and engineers with decades of viral vector manufacturing expertise.
End-to-end CMC support
Rigorous, quality-focused GMP processes with robust analytics.
Our GMP manufacturing pillars
Process & technology
- Expertise in transferring and scaling viral vector processes from other CDMOs or client facilities.
- Optimisation services across development and GMP scales (shake flask → 200L/500L/1,000L), supporting high-titer and complex vector production.
- Proprietary technologies and innovative platforms enhance productivity, product quality, and process robustness.
- Continuous innovation in media, upstream/downstream processing, perfusion, and automation.
Scale & capacity
- Extensive GMP capacity across UK, US, and France, supporting clinical and commercial supply.
- Flexible bioreactor systems from 200L to 2,000L, optimized for high-titer production and consistent performance.
- Dedicated GMP manufacturing suites with integrated fill-finish capabilities for end-to-end supply.
- Scalable processes designed to maintain potency, quality, and reproducibility across multiple vector types.
Expertise & people
- Experienced team guiding viral vector programs from clinical trials through commercial supply.
- Decades of combined industry knowledge in GMP manufacturing for multiple vector types.
- Skilled scientists and engineers driving process transfer, scale-up, and optimization.
- End-to-end CMC support backed by knowledgeable staff to navigate every stage of development.
- Robust quality systems and regulatory-compliant processes ensure reliable, consistent manufacturing.
Partner with OXB for GMP manufacturing excellence
Choose a manufacturing partner with proven expertise in process transfer, scale-up, and GMP supply. Contact OXB today to discuss how our GMP manufacturing services can support your program from clinic to commercial launch.
Explore OXB’s other CDMO solutions
Related resources
The TetraVecta™ System: Optimisation & Exemplification of OXB’s Next Generation Lentiviral Vector
View PDF >Enhancing Titres of Therapeutic Viral Vectors using the Transgene Repression in Vector Production TRiP System
This paper describes using a TRiP system to temporarily repress transgene expression during production, boosting viral vector titers for therapeutic use.
View PDF >Frequently asked questions
OXB offers end-to-end GMP manufacturing services for both lentiviral and AAV vectors. Our capabilities include process transfer, scale-up, large-scale bioreactor production (200L–2,000L), fill-finish, and commercial supply. All processes are performed under rigorous quality systems to ensure reproducible, high-yield, and regulatory-ready production.
Our global GMP facilities in the UK, US, and France provide flexible capacity to support clinical trials and commercial production. We ensure seamless scale-up, consistent quality, and reliable supply across all stages of your gene therapy program.
Yes. OXB’s integrated GMP processes are optimized for multiple vector types, delivering high-titer, reproducible, and compliant viral vector production for both lentivirus and AAV applications.
All GMP manufacturing processes at OXB are conducted under robust quality systems and validated procedures. Our experienced teams adhere to FDA, EMA, MHRA, and other global regulatory standards, ensuring reliable, regulatory-ready viral vector production.
OXB combines flexible bioreactor systems, integrated fill-finish suites, and standardized platform processes to scale production from clinical batches to full commercial supply while maintaining potency, quality, and reproducibility.
Our experienced scientists provide process transfer, development, and optimization services, leveraging proprietary platforms, automation, and analytical controls to ensure smooth scale-up and high-yield GMP manufacturing.
OXB’s combination of global GMP facilities, skilled personnel, scalable processes, and rigorous end-to-end quality controls enables reliable, efficient, and regulatory-compliant production of viral vectors from clinical trials through commercial launch.